Interferon as treatment for viral hepatitis: a progress report.

Research output: Contribution to journalArticle

Abstract

Treatment of chronic hepatitis with interferon is in its infancy and it is likely that information that we learn today will markedly improve the treatment that is offered tomorrow. The limitations of interferon treatment at the present time are the lack of complete predictable responses in approximately half the patients and the relatively high relapse rates observed thus far. It is predicted that higher doses will result in better response and lower relapse rates, but this remains to be seen. The cost and the frequency of side effects will likely be significantly increased by escalation of dose, but the chance of eradicating an otherwise untreatable and not benign condition is tempting and will continue to challenge our best efforts.

Original languageEnglish (US)
Pages (from-to)440-444
Number of pages5
JournalThe Journal of the South Carolina Medical Association
Volume86
Issue number8
StatePublished - Aug 1990

Fingerprint

Interferons
Hepatitis
Recurrence
Chronic Hepatitis
Therapeutics
Costs and Cost Analysis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Interferon as treatment for viral hepatitis : a progress report. / Lee, W. M.

In: The Journal of the South Carolina Medical Association, Vol. 86, No. 8, 08.1990, p. 440-444.

Research output: Contribution to journalArticle

@article{3f18905c77a74121a29ecf44d098316f,
title = "Interferon as treatment for viral hepatitis: a progress report.",
abstract = "Treatment of chronic hepatitis with interferon is in its infancy and it is likely that information that we learn today will markedly improve the treatment that is offered tomorrow. The limitations of interferon treatment at the present time are the lack of complete predictable responses in approximately half the patients and the relatively high relapse rates observed thus far. It is predicted that higher doses will result in better response and lower relapse rates, but this remains to be seen. The cost and the frequency of side effects will likely be significantly increased by escalation of dose, but the chance of eradicating an otherwise untreatable and not benign condition is tempting and will continue to challenge our best efforts.",
author = "Lee, {W. M.}",
year = "1990",
month = "8",
language = "English (US)",
volume = "86",
pages = "440--444",
journal = "The Journal of the South Carolina Medical Association",
issn = "0038-3139",
publisher = "South Carolina Medical Association",
number = "8",

}

TY - JOUR

T1 - Interferon as treatment for viral hepatitis

T2 - a progress report.

AU - Lee, W. M.

PY - 1990/8

Y1 - 1990/8

N2 - Treatment of chronic hepatitis with interferon is in its infancy and it is likely that information that we learn today will markedly improve the treatment that is offered tomorrow. The limitations of interferon treatment at the present time are the lack of complete predictable responses in approximately half the patients and the relatively high relapse rates observed thus far. It is predicted that higher doses will result in better response and lower relapse rates, but this remains to be seen. The cost and the frequency of side effects will likely be significantly increased by escalation of dose, but the chance of eradicating an otherwise untreatable and not benign condition is tempting and will continue to challenge our best efforts.

AB - Treatment of chronic hepatitis with interferon is in its infancy and it is likely that information that we learn today will markedly improve the treatment that is offered tomorrow. The limitations of interferon treatment at the present time are the lack of complete predictable responses in approximately half the patients and the relatively high relapse rates observed thus far. It is predicted that higher doses will result in better response and lower relapse rates, but this remains to be seen. The cost and the frequency of side effects will likely be significantly increased by escalation of dose, but the chance of eradicating an otherwise untreatable and not benign condition is tempting and will continue to challenge our best efforts.

UR - http://www.scopus.com/inward/record.url?scp=0025473189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025473189&partnerID=8YFLogxK

M3 - Article

C2 - 2120512

AN - SCOPUS:0025473189

VL - 86

SP - 440

EP - 444

JO - The Journal of the South Carolina Medical Association

JF - The Journal of the South Carolina Medical Association

SN - 0038-3139

IS - 8

ER -